Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 2,76€ (+236,59%). La mediana è 2,76€ (+236,59%).
| Acquista |
5 |
| Mantieni |
0 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Jaguar Health launches Neonorm Dog as a plant-based digestive solution for dogs
Jaguar Health has introduced Neonorm Dog, an over-the-counter plant-based product to support stool consistency and fluid balance in dogs’ gastrointestinal tract. The formulation contains a standardized extract from the Croton lechleri tree and complements the existing Neonorm line for foals and calves. Neonorm Dog will be sold through selected online and specialty channels such as Amazon and Chewy and is intended as an alternative to home remedies, not a replacement for veterinary care. » Altro su de.investing.com
Jaguar Health presents positive study data on crofelemer in pediatric intestinal failure
Jaguar Health reported data on liquid oral crofelemer in pediatric patients with intestinal failure showing a reduced need for parenteral support. In one patient with MVID, the weekly weight‑normalized requirement decreased by up to 48% after more than 12 months; two children with short bowel syndrome showed reductions of up to 40%. The treatment was well tolerated. The company intends to seek Breakthrough Therapy designation for crofelemer in MVID and plans an FDA approval submission in mid‑2027. » Altro su de.investing.com
Jaguar Health: coca leaf extract prevents weight gain in preclinical study
Jaguar Health reports that a coca leaf extract developed by Magdalena Biosciences prevented weight gain in mice on a high‑fat diet in a preclinical study at the University of Calgary without reducing food intake or activity. Magdalena Biosciences, a joint venture of Jaguar and Filament Health, is developing the extract as a prescription candidate to prevent weight regain after stopping GLP‑1 medications, in line with FDA botanical guidance. The study was supported by ENACO‑compliant coca leaves, and One Small Planet is providing funding of US$1 million. Jaguar is meanwhile under substantial financial pressure; the stock trades near its 52‑week low and the company shows a sharp share price decline and rapid cash burn. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 1.07m | 57,53% |
| Utile lordo | 169.98k | 91,83% |
| Utile netto | −11.11m | 25,85% |
| EBITDA | −10.70m | 26,10% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 52.61k€ |
Numero di azioni | 66.64k |
Massimo/minimo a 52 settimane | 73,33€ - 0,62€ |
| Dividendi | No |
Beta | -0,05 |
Rapporto P/E | 0,00 |
Rapporto PEG | 0,00 |
Rapporto P/B | 0,11 |
Rapporto P/S | 0,00 |
Profilo aziendale
Jaguar Health, Inc. ist ein kommerzielles Pharmaunternehmen, das sich auf die Entwicklung von verschreibungspflichtigen Medikamenten für Menschen und Tiere mit Magen-Darm-Beschwerden, insbesondere chronischer und schwächender Diarrhöe, konzentriert. Das Unternehmen ist in zwei Segmenten tätig: Human Health und Animal Health. Es vermarktet Mytesi für die symptomatische Linderung von nicht-infektiösem Durchfall bei Erwachsenen mit HIV/AIDS unter antiretroviraler Therapie. Das Unternehmen entwickelt außerdem Crofelemer für mehrere mögliche Folgeindikationen, darunter krebstherapiebedingte Diarrhö; Orphan-Drug-Indikationen zur symptomatischen Linderung von Durchfall bei Säuglingen und Kindern mit angeborenen Durchfallerkrankungen und bei erwachsenen und pädiatrischen Patienten mit Kurzdarmsyndrom mit Darminsuffizienz; unterstützende Behandlung zur Linderung von Durchfall bei entzündlichen Darmerkrankungen; durchfalldominantes Reizdarmsyndrom; und für idiopathische/funktionelle Diarrhöe. Darüber hinaus entwickelt das Unternehmen Lechlemer, ein sekretionshemmendes Mittel der zweiten Generation gegen Cholera, und Canalevia, einen oralen Arzneimittelkandidaten auf pflanzlicher Basis zur Behandlung von Chemotherapie-induzierter Diarrhö bei Hunden und von trainingsinduzierter Diarrhö bei Hunden. Jaguar Health, Inc. wurde 2013 gegründet und hat seinen Hauptsitz in San Francisco, Kalifornien.
| Nome | Jaguar Health |
| CEO | Lisa A. Conte |
| Sede centrale | San Francisco,
ca Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 13/05/2015 |
| Dipendenti | 47 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | JAGX |
Frankfurt | 1JA2.F |
Scopri gli asset
Gli azionisti di Jaguar Health investono anche nei seguenti asset
